Saccharomyces boulardii and Candida albicans experimental colonization of the murine gut

References

• McFarland LV, Surawicz CM, Greenberg RN, . Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995; 90: 439–448.
   PubMed Web of Science ®Google Scholar
• Surawicz CM, McFarland LV, Greenberg RN, . The search for a better treatment for Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000; 31: 1012–1017.
   PubMed Web of Science ®Google Scholar
• Saint-Marc T, Bléhaut H, Musial C, Touraine JL. Efficacité de Saccharomyces boulardii dans le traitement des diarrhées du SIDA. Am Med Int 1991; 142: 64–65.
   Google Scholar
• Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000; 45: 1462–1464.
   PubMed Web of Science ®Google Scholar
• Muller J, Remus N, Harms KH. Mycoserological study of the treatment of paediatric cystic fibrosis patients with Saccharomyces boulardii (Saccharomyces cerevisiae Hansen CBS 5926). Mycoses 1995; 38: 119–123.
   PubMedGoogle Scholar
• Lherm T, Monet C, Nougière B, . Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med 2002;28: 797–801.
   PubMed Web of Science ®Google Scholar
• Cesaro S, Chinello P, Rossi L, Zanesco L. Saccharomyces cerevisiae fungemia in a neutropenic patient treated with Saccharomyces boulardii. Support Care Cancer 2000; 8: 504–505.
   PubMed Web of Science ®Google Scholar
• Riquelme AJ, Calvo MA, Guzmán AM, . Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients. J Clin Gastroenterol 2003; 36: 41–43.
   PubMed Web of Science ®Google Scholar
• Niault M, Thomas F, Prost J, Ansari FH, Kalfon P. Fungemia due to Saccharomyces species in a patient treated with enteral Saccharomyces boulardii. Clin Infect Dis 1999; 28: 930.
   PubMed Web of Science ®Google Scholar
• Rijnders BJ, Van Wijngaerden E, Verwaest C, Peetermans WE. Saccharomyces fungemia complicating Saccharomyces boulardii treatment in a non-immunocompromised host. Int Care Med 2000; 26: 825.
   PubMed Web of Science ®Google Scholar
• Bléhaut H, Massot J, Elmer GW, Levy RH. Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharm Drug Disp 1989; 10: 353–364.
   PubMed Web of Science ®Google Scholar
• Barc MC, Charrin-Sarnel C, Rochet V, . Molecular analysis of the digestive microbiota in a gnotobiotic mouse model during antibiotic treatment: influence of Saccharomyces boulardii. Anaerobe 2008; 14: 229–233.
   Google Scholar
• Cartwright-Shamoon J, Dickson GR, Dodge J, Carr KE. Morphological aspects of particle translocation in vivo following ingestion of the yeast Saccharomyces boulardii. J Drug Target 1995; 3: 61–63.
   PubMed Web of Science ®Google Scholar
• Peret Filho LA, Penna FJ, Bambirra EA, Nicoli JR. Dose effect of oral Saccharomyces boulardii treatments on morbidity and mortality in immunosuppressed mice. J Med Microbiol 1998; 47: 111–116.
   PubMed Web of Science ®Google Scholar
• Samonis G, Anaissie EJ, Rosenbaum B, Bodey GP. A model of sustained gastrointestinal colonization by Candida albicans in healthy adult mice. Infect Immun 1990; 58: 1514–1517.
   PubMed Web of Science ®Google Scholar
• Freireich E, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966; 23: 265–273.
   Google Scholar
• Edwards-Ingram L, Gitsham P, Burton N, . Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiae. Appl Environ Microbiol 2007; 73: 2458–2467.
   PubMed Web of Science ®Google Scholar
• Buts JP, De Keyser N. Effects of Saccharomyces boulardii on intestinal mucosa. Dig Dis Sci 2006; 51: 1485–1492.
   PubMed Web of Science ®Google Scholar
• Lessard M, Dupuis M, Gagnon N, . Administration of Pediococcus acidilactici or Saccharomyces cerevisiae boulardii modulates development of porcine mucosal immunity and reduces intestinal bacterial translocation after Escherichia coli challenge. J Anim Sci 2009; 87: 922–934.
   PubMed Web of Science ®Google Scholar
• Kennedy MJ, Voltz PA. Dissemination of yeasts after gastrointestinal inoculation in antibiotic-treated mice. Sabouraudia 1983; 21: 27–33.
   PubMedGoogle Scholar
• Herbrecht R, Nivoix Y. Saccharomyces cerevisiae fungemia: an adverse effect of Saccharomyces boulardii probiotic administration. Clin Infect Dis 2005; 40: 1635–1637.
   PubMed Web of Science ®Google Scholar
• Samonis G, Gikas A, Anaissie EJ, . Prospective evaluation of effects of broad-spectrum antibiotics on gastrointestinal yeast colonization of humans. Antimicrob Agents Chemother 1993; 37: 51–53.
   PubMed Web of Science ®Google Scholar
• Samonis G, Maraki S, Leventakos K, . Comparative effects of ertapenem, imipenem, and meropenem on the colonization of the gastrointestinal tract of mice by Candida albicans. Med Mycol 2006; 44: 233–235.
   PubMed Web of Science ®Google Scholar
• Klein SM, Elmer GW, McFarland LV, Surawicz CM, Levy RH. Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii in healthy human volunteers. Pharm Res 1993; 10: 1615–1619.
   PubMed Web of Science ®Google Scholar
• Vanhoutte T, De Preter V, De Brandt E, . Molecular monitoring of healty human subjects during administration of lactulose and Saccharomyces boulardii. Appl Environ Microbiol 2006; 72: 5990–5997.
   PubMed Web of Science ®Google Scholar
• Buts JP, Bernasconi P, Van Craynest MP, Maldague P, De Meyer R. Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatr Res 1986; 20: 192–196.
   PubMed Web of Science ®Google Scholar
• Ducluzeau R, Bensaada M. Effect comparé de l'administration unique de Saccharomyces boulardii sur l'établissement de diverse souches de Candida dans le tractus digestif de souris gnotoxéniques. Ann Microbiol 1982; 133B: 491–501.
   Google Scholar
• Berg R, Bernasconi P, Fowler D, Gautreaux M. Inhibition of Candida albicans translocation from the gastrointestinal tract by oral administration of Saccharomyces boulardii. J Infect Dis 1993; 168: 1314–1318.
   PubMed Web of Science ®Google Scholar
• Corthier G, Dubos F, Ducluzeau R. Prevention of Clostridium difficile induced mortality in gnotobiotic mice by Saccharomyces boulardii. Can J Microbiol 1986; 32: 894–896.
   PubMed Web of Science ®Google Scholar
• Rodrigues AC, Nardi RM, Bambirra EA, Vieira EC, Nicoli JR. Effect of Saccharomyces boulardii against experimental oral infection with Salmonella typhimurium and Shigella flexneri in conventional and gnotobiotic mice. J Appl Bacteriol 1996; 81: 251–256.
   PubMedGoogle Scholar
• Jawhara S, Poulain D. Saccharomyces boulardii decreases inflammation and intestinal colonization by Candida albicans in a mouse model of chemically-induced colitis. Med Mycol 2007; 45: 691–700.
   PubMed Web of Science ®Google Scholar
• Akil I, Yilmaz O, Kurutepe S, Degerli K, Kavukcu S. Influence of oral intake of Saccharomyces boulardii on Escherichia coli in enteric flora. Pediatr Nephrol 2006; 21: 807–810.
   PubMedGoogle Scholar